|本期目录/Table of Contents|

[1]张萌,孟昭婷,张翠翠,等.Super-ARMS法检测EGFR突变在NSCLC的临床应用[J].天津医科大学学报,2021,27(02):185-187，203.
　ZHANG Meng,MENG Zhao-ting,ZHANG Cui-cui,et al.Clinical application of EGFR mutation in NSCLC detect by the way of Super-arms[J].Journal of Tianjin Medical University,2021,27(02):185-187，203.
点击复制

Super-ARMS法检测EGFR突变在NSCLC的临床应用(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
27卷
期数:
2021年02期
页码:
185-187，203
栏目:
技术与方法
出版日期:
2021-03-15

文章信息/Info

Title:
Clinical application of EGFR mutation in NSCLC detect by the way of Super-arms
文章编号:
1006-8147（2021）02-0185-04
作者:
张萌1; 2; 3; 孟昭婷2; 张翠翠2; 朱富艺1; 2; 左冉1; 2; 陈鹏1; 2
（1.天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津300060；2.天津医科大学研究生院，天津 300070；3.邯郸市第一医院，邯郸 056000）
Author(s):
ZHANG Meng1; 2; 3;  MENG Zhao-ting2;  ZHANG Cui-cui2;  ZHU Fu-yi1; 2;  ZUO Ran1; 2;  CHEN Peng1; 2
（1.Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin′s Clinical Research Center for Eancer，Tianjin 300060，China；2.Graduate School，Tianjin M
关键词:
非小细胞肺癌; 表皮生长因子受体酪氨酸激酶抑制剂; EGFR; Super-ARMS
Keywords:
non-small cell lung cancer; epidermal growth factor receptor tyrosine kinase inhibitor; EGFR; Super-ARMS
分类号:
R734.2
DOI:
-
文献标志码:
A
摘要:
目的：探讨Super-ARMS法检测体液EGFR突变在晚期非小细胞肺癌（NSCLC）患者治疗中的应用。方法：收集天津医科大学肿瘤医院自2019年4月1日—2019年12月30日161例NSCLC患者的血液、脑脊液、心包积液标本，采用Super-ARMS法对EGFR基因片段进行检测，根据突变结果对EGFR突变类型分析判断。结果：161例NSCLC患者标本中，86例（53.4％）EGFR突变阳性。19号外显子（19-del）缺失、21号外显子（L858R）基因点突变及T790M点突变最常见。S768I有5例（3.1%）；G719X突变4例（2.5％）；L861Q有1例（0.6%）；不同性别、是否吸烟者之间突变差异均无统计学意义（均P>0.05）；在年龄、是否存在EGFR-TKIs治疗史间差异均有统计学意义（均P<0.05）。EGFR基因突变率在女性、不吸烟患者中较高。结论：NSCLC患者EGFR突变率较高。Super-ARMS法可用于体液EGFR突变检测，其结果较准确，且可同时检测多种突变及并存突变。
Abstract:
Objective: To investigate the application of Super-Arms in the detection of humoral EGFR mutation in the treatment of advanced NSCLC patients. Methods: A total of 161 patients diagnosed NSCLC between Apr 1，2019 and Dec 30，2019 were enrolled in the present study. EGFR mutations extracted from blood， cerebrospinal fluid and pericardial effusion samples were dectected using Super-ARMS. EGFR mutation was analyzed and determined according to the mutation results. Results: Of 161 NSCLC patients，86 （53.4%） were positive for EGFR mutation. Exon 19 deletion， L858R point mutation and T790M point mutation were the most common ones. S768I had 5 cases （3.1%）； 4 patients with G719X mutation （2.5%）. There was 1 case of L861Q（0.6%）. There was no statistically significant difference in mutation between different genders or smokers（all P>0.05）. There were statistically significant differences in age and history of EGFR-TKIs（all P<0.05）. EGFR mutation rate was significantly higher in female and non-smoking patients. Conclusion: NSCLC patients have higher EGFR mutation rate. Super-ARMS can be used to detect EGFR mutations in body fluids， with relatively accurate results， and can detect multiple mutations and concurrent mutations simultaneously.

参考文献/References:

[1] 王丽萍. 非小细胞肺癌的靶向和免疫治疗进展[J]. 郑州大学学报（医学版），2020，55（2）:477
[2] Minguet J，Smith K H，Bramlage P. Targeted therapies for treatment of nonsmall cell lung cancer-recent advances and future perspectives[J]. Int J Cancer， 2016，138（11）：2549
[3] 胡鹏程，耿僡临，魏慎海，等. 抗晚期非小细胞肺癌靶向治疗的研究进展[J]. 山东医药，2020，60 （16）：102
[4] Lee Y T， Tan Y J， Oon C E. Molecular targeted therapy： treating cancer with specificity[J]. Eur J Pharmacol， 2018 ，834（1）：188
[5] Singh D， Attri B K， Gill R K， et al. Review on EGFR inhibitors： critical updates[J]. Mini Rev Med Chem， 2016，16（14）：1134
[6] Sheikine Y， Kuo F C， Lindeman N I. Clinical and technical aspects of genomic diagnostics for precision oncology[J]. J Clin Oncol，2017， 35（9）：929
[7] Jiang H Y. Association between EGFR mutation status and efficacy of first-line EGFR-TKI in patients with advanced non-small cell lung cancer[J]. J International Oncol，2017，44（1）：19
[8] Ku BM， Sun J M， Lee S H， et al. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer[J]. Expert Rev Mol Diagn， 2017，17（10）：933
[9] Nosaki K，Satouchi M，Kurata T，et al. Re-biopsy status among non-small cell lung cancer patients in Japan：a retrospective study[J]. Lung Cancer，2016，101（1）：1
[10] Diaz L A， Bardelli A. Liquid biopsies： genotyping circulating tumor DNA[J]. J Clin Oncol， 2014，32（6）： 579
[11] Bettgowda C，Sausen M，Leary R J，et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med，2014，6（224）： 224
[12] Wan J， Massie C， Garcia-corbacho J， et al. Liquid biopsies come of age： towards implementation of circulating tumour DNA[J]. Nat Rev Cancer， 2017，17（4）： 223
[13] Patel K M，Tsui D W. The translational potential of circulating tumour DNA in oncology[J]. Clin Bio Chem， 2015，48（1）：957
[14] Li B T，Drilon A，Johnson M L，et al. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers[J]. Ann Oncol，2016，27（1）：154
[15] Shi Y， Li J， Zhang S， et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-mainland China subset analysis of the PIONEER study[J]. PLOS One，2015，10（11）：e0143515

相似文献/References:

[1]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(03):51.
　LIANG Shao-ping,WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(02):51.
[2]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(01):51.
　LIANG Shao-ping WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(02):51.
[3]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(02):417.
[4]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(02):417.
[5]黄晓莹.MRI与CT在非小细胞肺癌淋巴结转移诊断中的应用价值比较[J].天津医科大学学报,2017,23(06):542.
　HUANG Xiao-ying.Application value of MRI and CT in the diagnosis of lymph node metastasis of non-small cell lung cancer[J].Journal of Tianjin Medical University,2017,23(02):542.
[6]高会霞,王 彬,方 黎,等.3DCRT联合化疗对晚期NSCLC患者近期疗效及血清肿瘤标记物的影响[J].天津医科大学学报,2019,25(05):507.
[7]王红军,贾金广,朱婉凌,等.CXCL-14在非小细胞肺癌中的表达水平及临床意义[J].天津医科大学学报,2021,27(02):112.
　WANG Hong-jun,JIA Jin-guang,ZHU Wan-ling,et al.The expression level and clinical significance of CXCL-14 in non-small cell lung cancer[J].Journal of Tianjin Medical University,2021,27(02):112.
[8]严一杰,张军,王硕,等.125I粒子植入的靶区勾画对一线治疗后局部进展的非小细胞肺癌治疗效果影响[J].天津医科大学学报,2021,27(06):586.
　YAN Yi-jie,ZHANG Jun,WANG Shuo,et al.Effect of target delineation of 125I seed implantation on the treatment of locally advanced non-small cell lung cancer after first-line therapy[J].Journal of Tianjin Medical University,2021,27(02):586.
[9]陈嫱,英硕,李冠华,等.非小细胞肺癌M1期患者的危险、预后因素和转移特征：一项基于SEER数据库的研究[J].天津医科大学学报,2022,28(01):27.
　CHEN Qiang,YING Shuo,LI Guan-hua,et al.The risk，prognostic factors and metastatic features for patients with M1 stage of non-small cell lung cancer: a SEER-based study[J].Journal of Tianjin Medical University,2022,28(02):27.
[10]张思培,陈丽娟,秦建文,等.肺腺癌合并活动性肺结核患者用药讨论1例[J].天津医科大学学报,2023,29(04):440.

备注/Memo

备注/Memo:
基金项目 天津医科大学肿瘤医院临床试验基金一般项目（C1712）
作者简介 张萌（1992-），女，医师，硕士在读，研究方向：肺部肿瘤；通信作者：陈鹏，E-mail:chenpengdoc@sina.com。
更新日期/Last Update: 2021-03-10